Objective. IgG aPL against domain I of β 2-glycoprotein I (β 2 GPI)[anti-DI (aDI)] is
associated with the pathogenesis of APS, an autoimmune disease defined by thrombosis …

Objectives: In the antiphospholipid syndrome (APS), the immunodominant epitope for the
majority of circulating pathogenic antiphospholipid antibodies (aPLs) is the N-terminal …

APS is an autoimmune disease in which antiphospholipid antibodies (aPL) cause vascular
thrombosis and pregnancy morbidity. In patients with APS, aPL exert pathogenic actions by …

Objective The presence of autoantibodies against a cryptic epitope in domain I of β2‐
glycoprotein I (β2GPI) is strongly associated with thrombotic events in patients with the …

Antiphospholipid syndrome (APS) is an autoimmune disorder with increased risk for
thrombosis and pregnancy losses. β2-glycoprotein I (β2GPI) is the major antigen for …

Objective Pathogenic antiphospholipid antibodies (aPL) bind the self antigen N‐terminal
domain (domain I) of β2‐glycoprotein I (β2GPI), with residues G40–R43 being important …

Objective To examine the prevalence of isolated IgA anti–β2‐glycoprotein I (anti‐β2GPI)
positivity and the association of these antibodies, and a subgroup that bind specifically to …

Abstract β2-glycoprotein I (β2GPI) is the major antigenic target for antiphospholipid Abs. Anti-
β2GPI Abs are a heterogeneous population of Igs targeting all domains of the molecule. Abs …

Antiphospholipid antibodies (aPL), the serological hallmark of antiphospholipid syndrome
(APS), are a heterogeneous group of autoantibodies raised against circulating blood …

Autoantibodies characteristic for anti-phospholipid syndrome (APS) and systemic lupus
erythematosus (SLE) are anti-β2-glycoprotein I (β2GPI) antibodies and anti-DNA antibodies …